Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...

Iambic Therapeutics (IAM) priced its IPO at $16.00 – the mid-point – and sold 9.38 million shares – the number in the prospectus – to raise $150 million on Wednesday night, Oct. 14. The Phase I cancer ...

QIMA Life Sciences launches SQINGEVITY, bringing biological testing and clinical studies together to examine claims about ...

OMass Therapeutics, an Oxford spin-out built on native mass spectrometry, has raised £230 million (about $310 million) in a Series C that CEO ...

Hold: $1.2bn Zealand obesity deal, GB-0895 Phase 3 asthma readout vs Tezspire, cash burn risks, AI platform optionality—read ...

While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s ...

Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access.

When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition ...

Validation is the new bottleneck. AI-native biotechs are pairing computational design with wet-lab confirmation and in vivo pharmacology, because a design only gains value once it holds up ...

Your immune cells are constantly aging. Cellino is launching a new service, called Reservoir, to let people securely store ...

Dow futures rose with yields falling. Chip-gear giant ASML beat on earnings with the CPI inflation report due.. Meta and AMD ...